Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18726574 | 1.00 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL574827 | 1.00 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL18726765 | 0.94 | HDAC1 (0.40) | HDAC1HDAC2LMNAALDH1A1EHMT2 | |
| SCHEMBL18896133 | 0.90 | HDAC1 (0.36) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9904994 | 0.90 | HDAC1 (0.36) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL18656418 | 0.87 | HDAC1 (0.36) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15994284 | 0.87 | HPGD (0.38) | HDAC1HDAC2LMNAALDH1A1MAPT | |
| SCHEMBL18052247 | 0.86 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL29427565 | 0.86 | HDAC1 (0.34) | HDAC1HDAC2 | |
| SCHEMBL19188153 | 0.85 | HDAC1 (0.36) | HDAC1HDAC2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 981 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075735-A | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates | — | 2026-05-26 | — | — | CN | claimed |
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4719483-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES, ANTI-PD1/PD-L1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | Sanofi (FR) | 2026-04-08 | — | — | EP | claimed |
| EP-4713024-A1 | CONJUGATE AND THE PREPARATION THEREOF | Nanjing University (CN) | 2026-03-25 | — | — | EP | claimed |
| US-12570761-B2 | Anti-CEACAM5 antibodies and uses thereof | SANOFI (FR) | 2026-03-10 | — | — | US | claimed |
| US-20260061066-A1 | ANTI-GRP78 ANTIBODY, IMMUNOCONJUGATE AND USES THEREOF | UCT BIOSCIENCE CO., LTD. (TW) | 2026-03-05 | — | — | US | claimed |
| EP-4688000-A1 | ANTIBODY DRUG CONJUGATES | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4676541-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES, ANTI-VEGFR-2 ANTIBODIES AND ANTI-PD1/PD-L1 ANTIBODIES | Sanofi (FR) | 2026-01-14 | — | — | EP | claimed |
| EP-4673181-A1 | USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING NEUROENDOCRINE CANCERS EXPRESSING CEACAM5 | Sanofi (FR) | 2026-01-07 | — | — | EP | claimed |
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20220143208-A1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN, INC. (US) | 2022-05-12 | — | — | US | claimed |
| US-20220133899-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | IMMUNOGEN INC. | 2022-05-05 | — | — | US | claimed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | claimed |
| US-20220105198-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | IMMUNESENSOR THERAPEUTICS, INC. | 2022-04-07 | — | — | US | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| US-20220080053-A1 | USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING LUNG CANCER | SANOFI (FR) | 2022-03-17 | — | — | US | claimed |
| US-11274121-B2 | Methods for antibody drug conjugation, purification, and formulation | IMMUNOGEN, INC. (US) | 2022-03-15 | — | — | US | claimed |
| CN-114173823-A | Use of anti-CEACAM 5 immunoconjugates for treating lung cancer | 赛诺菲 | 2022-03-11 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2022046941-A1 | ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2022-03-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570761-B2 | Anti-CEACAM5 antibodies and uses thereof | TNFRSF9, IGSF11, FCGR2A | HDAC1 4725/4885HDAC2 4752/4885LMNA 2950/4885 |
| US-20220105198-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | STING1, CGAS, MAVS | HDAC1 4835/4885HDAC2 4695/4885LMNA 2981/4885 |
| US-20220080053-A1 | USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING LUNG CANCER | EPCAM, BSG, SIGLEC9 | HDAC1 4029/4885HDAC2 3859/4885LMNA 3168/4885 |
| US-20220133899-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | CD47, CD22, CLSPN | HDAC1 3862/4885HDAC2 4221/4885LMNA 2916/4885 |
| US-20260061066-A1 | ANTI-GRP78 ANTIBODY, IMMUNOCONJUGATE AND USES THEREOF | IGSF11, DNAJC10, HSPA5 | HDAC1 4660/4885HDAC2 4529/4885LMNA 4229/4885 |
| US-11274121-B2 | Methods for antibody drug conjugation, purification, and formulation | FCGR2A, FCGR1A, FCGR3B | HDAC1 4077/4885HDAC2 3412/4885LMNA 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.